207 related articles for article (PubMed ID: 11040449)
1. DMSO and glycerol reduce bacterial death induced by expression of truncated N-terminal huntingtin with expanded polyglutamine tracts.
Nagao Y; Ishiguro H; Nukina N
Biochim Biophys Acta; 2000 Oct; 1502(2):247-56. PubMed ID: 11040449
[TBL] [Abstract][Full Text] [Related]
2. Rapid aggregate formation of the huntingtin N-terminal fragment carrying an expanded polyglutamine tract.
Hazeki N; Nakamura K; Goto J; Kanazawa I
Biochem Biophys Res Commun; 1999 Mar; 256(2):361-6. PubMed ID: 10079189
[TBL] [Abstract][Full Text] [Related]
3. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture.
Cooper JK; Schilling G; Peters MF; Herring WJ; Sharp AH; Kaminsky Z; Masone J; Khan FA; Delanoy M; Borchelt DR; Dawson VL; Dawson TM; Ross CA
Hum Mol Genet; 1998 May; 7(5):783-90. PubMed ID: 9536081
[TBL] [Abstract][Full Text] [Related]
4. A cellular model that recapitulates major pathogenic steps of Huntington's disease.
Lunkes A; Mandel JL
Hum Mol Genet; 1998 Sep; 7(9):1355-61. PubMed ID: 9700187
[TBL] [Abstract][Full Text] [Related]
5. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release.
Jana NR; Zemskov EA; Wang Gh ; Nukina N
Hum Mol Genet; 2001 May; 10(10):1049-59. PubMed ID: 11331615
[TBL] [Abstract][Full Text] [Related]
6. Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin.
Bao J; Sharp AH; Wagster MV; Becher M; Schilling G; Ross CA; Dawson VL; Dawson TM
Proc Natl Acad Sci U S A; 1996 May; 93(10):5037-42. PubMed ID: 8643525
[TBL] [Abstract][Full Text] [Related]
7. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.
Wyttenbach A; Swartz J; Kita H; Thykjaer T; Carmichael J; Bradley J; Brown R; Maxwell M; Schapira A; Orntoft TF; Kato K; Rubinsztein DC
Hum Mol Genet; 2001 Aug; 10(17):1829-45. PubMed ID: 11532992
[TBL] [Abstract][Full Text] [Related]
8. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease.
Ho LW; Brown R; Maxwell M; Wyttenbach A; Rubinsztein DC
J Med Genet; 2001 Jul; 38(7):450-2. PubMed ID: 11432963
[TBL] [Abstract][Full Text] [Related]
9. Decreased cAMP response element-mediated transcription: an early event in exon 1 and full-length cell models of Huntington's disease that contributes to polyglutamine pathogenesis.
Sugars KL; Brown R; Cook LJ; Swartz J; Rubinsztein DC
J Biol Chem; 2004 Feb; 279(6):4988-99. PubMed ID: 14627700
[TBL] [Abstract][Full Text] [Related]
10. Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats.
Li SH; Li XJ
Hum Mol Genet; 1998 May; 7(5):777-82. PubMed ID: 9536080
[TBL] [Abstract][Full Text] [Related]
11. Effects of overexpression of huntingtin proteins on mitochondrial integrity.
Wang H; Lim PJ; Karbowski M; Monteiro MJ
Hum Mol Genet; 2009 Feb; 18(4):737-52. PubMed ID: 19039036
[TBL] [Abstract][Full Text] [Related]
12. Amyloid formation by mutant huntingtin: threshold, progressivity and recruitment of normal polyglutamine proteins.
Huang CC; Faber PW; Persichetti F; Mittal V; Vonsattel JP; MacDonald ME; Gusella JF
Somat Cell Mol Genet; 1998 Jul; 24(4):217-33. PubMed ID: 10410676
[TBL] [Abstract][Full Text] [Related]
13. Mutant huntingtin forms in vivo complexes with distinct context-dependent conformations of the polyglutamine segment.
Persichetti F; Trettel F; Huang CC; Fraefel C; Timmers HT; Gusella JF; MacDonald ME
Neurobiol Dis; 1999 Oct; 6(5):364-75. PubMed ID: 10527804
[TBL] [Abstract][Full Text] [Related]
14. Polyglutamine pathogenesis.
Ross CA; Wood JD; Schilling G; Peters MF; Nucifora FC; Cooper JK; Sharp AH; Margolis RL; Borchelt DR
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1005-11. PubMed ID: 10434299
[TBL] [Abstract][Full Text] [Related]
15. Molecular aspects of Huntington's disease.
Walling HW; Baldassare JJ; Westfall TC
J Neurosci Res; 1998 Nov; 54(3):301-8. PubMed ID: 9819135
[TBL] [Abstract][Full Text] [Related]
16. Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells.
Chun W; Lesort M; Tucholski J; Faber PW; MacDonald ME; Ross CA; Johnson GV
Neurobiol Dis; 2001 Jun; 8(3):391-404. PubMed ID: 11442349
[TBL] [Abstract][Full Text] [Related]
17. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
18. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity.
Jana NR; Tanaka M; Wang Gh; Nukina N
Hum Mol Genet; 2000 Aug; 9(13):2009-18. PubMed ID: 10942430
[TBL] [Abstract][Full Text] [Related]
19. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification.
Evers MM; Tran HD; Zalachoras I; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Nucleic Acid Ther; 2014 Feb; 24(1):4-12. PubMed ID: 24380395
[TBL] [Abstract][Full Text] [Related]
20. In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease.
Hackam AS; Singaraja R; Zhang T; Gan L; Hayden MR
Hum Mol Genet; 1999 Jan; 8(1):25-33. PubMed ID: 9887328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
